Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns
| Autor: | H. Wollschläger, J. Ruof, G. Klein, Winfried März, A. Neiss, Martin Wehling |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Epidemiology Atorvastatin Population Coronary Disease Physical examination Germany Internal medicine Ambulatory Care medicine Humans Dosing Practice Patterns Physicians' education Triglycerides Aged Hypolipidemic Agents Retrospective Studies Analysis of Variance education.field_of_study medicine.diagnostic_test business.industry Therapeutic effect Public Health Environmental and Occupational Health Cholesterol LDL Middle Aged Discontinuation Surgery Clinical trial Simvastatin Practice Guidelines as Topic Female lipids (amino acids peptides and proteins) business medicine.drug |
| Zdroj: | Preventive Medicine. 35:48-53 |
| ISSN: | 0091-7435 |
| DOI: | 10.1006/pmed.2002.1050 |
| Popis: | Background. Few published data in particular from the United States indicate that the implementation of guidelines for prevention of coronary heart disease (CHD) is far from optimal. The objective of our study was to identify the type and prevalence of lipid-lowering medications in a German outpatient CHD population and to examine the impact of applied treatment regimens on serum lipid levels. Methods. Retrospective analysis of the washout phase of 2,856 CHD patients requiring lipid-lowering medication. Data are derived from a multicenter, randomized, open-label, parallel group clinical trial comparing the safety and efficacy of atorvastatin versus simvastatin in 591 centers in Germany. Medical history, physical examination, and serum lipid levels were obtained at the beginning of the washout phase (Week −6) and at the end of the washout phase (Week −1, i.e., 5 weeks after the discontinuation of all prior lipid-lowering medications). The data at Week −6 represented the lipid levels under real life conditions. The difference from the data at Week −1 reflected the therapeutic effects achieved by the previous lipid-lowering treatment. Results. The mean low-density lipoprotein cholesterol (LDL-C) level at Week −6 was 173.4 ± 42.5 mg/dl. Only 176 (6.2%) of 2,856 CHD patients were found to meet the target LDL-C level of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect